Anti-CD20 in Systemic Lupus Erythematosus

Completed · Phase 1/Phase 2

Conditions studied: Lupus Erythematosus, Systemic

In brief

The purpose of this study is to determine the safety and effectiveness of rituximab (anti-CD20) in treating systemic lupus erythematosus (SLE). White blood cells in the body called B cells give off substances that are active in promoting SLE disease. Researchers have found that anti-CD20 can block production of these substances in another disease. This study explores whether anti-CD20 will also be safe in people with SLE and whether it may be effective in treating SLE.

Key facts

Study ID

NCT00036491

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

24

Starts

2001-01-01

Expected to finish

2006-01-01

Last updated by the study team

2017-11-06

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• People may be eligible for this study if they:
• Are 18 to 70 years of age
• Agree to use a reliable method of birth control during treatment and for 6 months after treatment ends
• Have SLE (by the American College of Rheumatology criteria)
• Have had SLE for at least 6 months prior to screening
• Have active SLE disease at the screening visit
• Have organ disease (lung, stomach, intestinal, blood, kidney, and/or heart)
• Have failed standard therapy, including at least 1 immunosuppressive agent, or have experienced side effects from an immunosuppressive agent that required discontinuation of treatment
• Meet blood, liver, and kidney laboratory values set by the protocol
• Have not taken an immunosuppressive agent for 2 weeks prior to the first treatment
• Have been on a stable dose of oral corticosteroids, if taking them, for 4 weeks before the first week's visit. Oral corticosteroids may be altered as medically necessary after enrollment.
• Have at least 1 elevated autoantibody level at screening visit.

You may not qualify if…

• People will not be eligible for this study if they:
• Are pregnant or breast-feeding
• Have heart, lung, nervous system, kidney, liver, stomach, intestinal, or other diseases that may place the patient at risk if participating in the trial
• Have cranial neuropathy (a condition affecting the head region)
• Are on blood-thinning agents to prevent blood clotting
• Have a serious skin disease
• Have a certain class of heart disease
• Have had cancer, unless surgically cured basal cell carcinoma or cervical dysplasia
• Have a long term serious infectious disease such as tuberculosis or a fungal infection that is now active, or active within 2 years of the baseline visit
• Have had HIV infection or another immunosuppressive state (chemotherapy or radiation therapy)
• Have received any experimental drug within 30 days of baseline visit
• Have received any monoclonal antibody or similar medication within 3 months of the baseline visit
• Received any intravenous, joint, or muscle injection of corticosteroids within 4 weeks of the baseline visit
• Abuse alcohol or drugs
• Are unwilling or unable to follow the protocol
• Have poor veins for receiving injections.

Where it is running

• University of Colorado — Denver, Colorado, United States
• University of Rochester — Rochester, New York, United States
• University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.